Immunic Inc
NASDAQ:IMUX

  • LAST PRICE
    1.1400
  • TODAY'S CHANGE (%)
    -0.0400 (-3.3898%)
  • Bid / Lots
    1.1600/ 21
  • Ask / Lots
    1.2500/ 5
  • Open / Previous Close
    1.2000 / 1.1800
  • Day Range
    1.1300
    1.2100
  • 52 Week Range
    0.9700
    2.1100
  • Volume
    642,272

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Today

      Show headlines and story abstract

    • 16 hours ago by PR Newswire
      Companies Mentioned: IMUX

      Immunic, Inc.(Nasdaq: IMUX),a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Thursday, December 5, 2024, at 11:30 am ET, during the Piper Sandler 36th Annual Healthcare Conference, taking place December 3-5, 2024, in New York.

    • 16 hours ago by Dow Jones
      Companies Mentioned: IMUX

      Immunic, Inc. to Participate in Investor Conference in December

      PR Newswire

      NEW YORK, Nov. 26, 2024

      NEW YORK, Nov. 26, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Thursday, December 5, 2024, at 11:30 am ET, during the Piper Sandler 36th Annual Healthcare Conference, taking place December 3-5, 2024, in New York.

  • Yesterday

  • Nov 13, 2024

      Show headlines and story abstract

    • 6:30AM ET on Wednesday Nov 13, 2024 by PR Newswire
      Companies Mentioned: IMUX

      Includes Phase 1 Data in Healthy Human Subjects and Phase 1b Data in Celiac Disease Patients -

      Immunic, Inc.(Nasdaq: IMUX),a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the data from its phase 1/1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), has been published in the peer reviewed journal, The Lancet Gastroenterology & Hepatology. Lead authored by Dr. A. James Daveson, Gastroenterologist, Wesley Research Institute and Coral Sea Clinical Research Institute, Queensland, Australia, the paper is entitled, "Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial." It can be accessed through the following link: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00248-6/fulltext.

    • 6:30AM ET on Wednesday Nov 13, 2024 by Dow Jones
      Companies Mentioned: IMUX

      future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 22, 2024, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Peers Headlines